Combined 18F-FDG and fluoride approach in PET/CT imaging: Is there a clinical future? [1]

Journal of Nuclear Medicine

Volumn 51, Issue 1, 2010, Pages 165-

  Basu, Sandip ^a   Rao, Ramesh ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

CANCER LOCALIZATION; CANCER RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LETTER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; THYROID CARCINOMA; METHODOLOGY; NEOPLASM; NOTE;

FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 75149116680     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066860     Document Type: Letter

References (4)

1. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501-505.
2. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253-258.
3. Basu S, Torigian D, Alavi A. Evolving concept of imaging bone marrow metastasis in the 21st century: critical role of FDG-PET [editorial]. Eur J Nucl Med Mol Imaging. 2008;35:465-471.
4. Basu S, Alavi A. Defining co-related parameters between 'metabolic' flare with those of 'clinical', 'biochemical' and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging. 2007;34:441-443.